| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Haremaru Kubo, Kazuhiro Sugimoto, Ryota Wada, Naohiro Sekikawa, Minoru Inou. A Case of Acromegaly With Progressed Diabetic Retinopathy and Sarcopenia Diagnosed Following the Onset of Severe Hypoglycemia. Cureus. vol 16. issue 4. 2024-05-21. PMID:38765413. |
acromegaly is a rare disorder characterized by excessive production of growth hormone (gh) from a pituitary tumor, typically leading to elevated glucose levels due to increased insulin resistance; hypoglycemia is rare. |
2024-05-21 |
2024-05-27 |
Not clear |
| Betina Biagetti, Marta Araujo-Castro, Edelmiro Menéndez Torre, Iría Novoa-Testa, Fernando Cordido, Eider Pascual Corrales, Víctor Rodríguez Berrocal, Fernando Guerrero-Pérez, Almudena Vicente, Juan Carlos Percovich, Rogelio García Centeno, Laura González, María Dolores Ollero García, Ana Irigaray Echarri, María Dolores Moure Rodríguez, Cristina Novo-Rodríguez, María Calatayud, Rocío Villar-Taibo, Ignacio Bernabéu, Cristina Alvarez-Escola, Pamela Benítez Valderrama, Carmen Tenorio, Pablo Abellán Galiana, Eva Venegas Moreno, Inmaculada González Molero, Pedro Iglesias, Concepción Blanco, Fernando Vidal-Ostos De Lara, Paz de Miguel, Elena López Mezquita, Felicia Hanzu, Iban Aldecoa, Silvia Aznar, Cristina Lamas, Anna Aulinas, Queralt Asla, Paola Gracia, José María Recio Córdova, Mariola Aviles, Diego Asensio-Wandosel, Miguel Sampedro, Rosa Cámara, Miguel Paja, Ignacio Ruz-Caracuel, Carmen Fajardo-Montañana, Esteban Cordero Asanza, Elena Martinez-Saez, Mónica Marazuela, Manel Puig-Doming. Effectiveness of Combined First-Line Medical Treatment in Acromegaly with Prolactin Co-secretion. European journal of endocrinology. 2024-05-21. PMID:38771697. |
to compare the response to first-line medical treatment in treatment-naive acromegaly patients with pure growth hormone (gh)-secreting pituitary adenoma (gh-pa) and those with gh and prolactin co-secreting pa (gh&prl-pa). |
2024-05-21 |
2024-05-27 |
Not clear |
| Megana Murugesh, Franklin Llereña Thelmo, Monika Khanna Shirodka. Uncontrolled Acromegaly Resulting in the Need for Left Ventricular Assist Device as Bridge to Heart Transplant. JCEM case reports. vol 2. issue 5. 2024-05-16. PMID:38746051. |
acromegaly is a rare pituitary condition stemming from hypersecretion of growth hormone (gh). |
2024-05-16 |
2024-05-27 |
Not clear |
| Marta Araujo-Castro, Betina Biagetti, Edelmiro Menedez-Torre, Iría Novoa-Testa, Fernando Cordido, Eider Pascual-Corrales, Víctor Rodríguez Berrocal, Fernando Guerrero-Pérez, Almudena Vicente, Juan Carlos Percovich Hualpa, Rogelio Garcia Centeno, Laura González Fernández, María Dolores Ollero García, Ana Irigaray Echarri, María Dolores Moure Rodríguez, Cristina Novo-Rodríguez, María Calatayud, Rocío Villar, Ignacio Bernabéu, Cristina Alvarez-Escola, Pamela Benítez Valderrama, Carmen Tenorio, Pablo Abellán Galiana, Eva Venegas, Inmaculada González-Molero, Pedro Iglesias, Concepción Blanco-Carrera, Fernando Vidal-Ostos De Lara, Paz de Miguel Novoa, Elena López Mezquita, Felicia Alexandra Hanzu, Iban Aldecoa, Silvia Aznar, Cristina Lamas, Anna Aulinas, Anna Queralt Asla, Paola Gracia Gimeno, José María Recio Córdova, Mariola Aviles, Diego Asensio-Wandosel, Miguel Sampedro-Núñez, Rosa Camara, Miguel Paja Fano, Ignacio Ruz-Caracuel, Carmen Fajardo, Mónica Marazuela, Manel Puig-Doming. Pegvisomant or pasirotide in PRL and GH co-secreting vs GH-secreting Pit-NETs. Endocrine-related cancer. 2024-05-07. PMID:38713182. |
to evaluate the efficacy of second-line therapies in patients with acromegaly caused by a growth hormone (gh) and prolactin (prl) co-secreting pituitary neuroendocrine tumor (gh/prl-pit-net) and compare to those caused by a gh-pit-net. |
2024-05-07 |
2024-05-27 |
Not clear |
| Miguel Sampedro-Nuñez, Aura Dulcinea Herrera-Martínez, Alejandro Ibáñez-Costa, Esther Rivero-Cortés, Eva Venegas, Mercedes Robledo, Rebeca Martínez-Hernández, Araceli García-Martínez, Joan Gil, Mireia Jordà, Judith López-Fernández, Inmaculada Gavilán, Silvia Maraver, Montserrat Marqués-Pamies, Rosa Cámara, Carmen Fajardo-Montañana, Elena Valassi, Elena Dios, Anna Aulinas, Betina Biagetti, Cristina Álvarez Escola, Marta Araujo-Castro, Concepción Blanco, Paz de Miguel, Rocío Villar-Taibo, Clara V Álvarez, Sonia Gaztambide, Susan M Webb, Luis Castaño, Ignacio Bernabéu, Antonio Picó, María-Ángeles Gálvez, Alfonso Soto-Moreno, Manel Puig-Domingo, Justo P Castaño, Mónica Marazuela, Raúl M Luqu. Integrative Clinical, Hormonal and Molecular Data associate with Invasiveness in Acromegaly: REMAH Study. European journal of endocrinology. 2024-05-03. PMID:38701338. |
growth-hormone (gh)-secreting pituitary-tumors (ghomas) are the most common acromegaly cause. |
2024-05-03 |
2024-05-06 |
Not clear |
| Steve Orme, Richard McNally, Peter W James, Jessica Davis, John Ayuk, Claire Higham, John Was. Increased mortality in acromegaly is due to vascular and respiratory disease and is normalised by control of GH levels-A retrospective analysis from the UK Acromegaly Register 1970-2016. Clinical endocrinology. 2024-04-23. PMID:38652736. |
increased mortality in acromegaly is due to vascular and respiratory disease and is normalised by control of gh levels-a retrospective analysis from the uk acromegaly register 1970-2016. |
2024-04-23 |
2024-04-26 |
Not clear |
| Steve Orme, Richard McNally, Peter W James, Jessica Davis, John Ayuk, Claire Higham, John Was. Increased mortality in acromegaly is due to vascular and respiratory disease and is normalised by control of GH levels-A retrospective analysis from the UK Acromegaly Register 1970-2016. Clinical endocrinology. 2024-04-23. PMID:38652736. |
epidemiological studies involving patients with acromegaly have yielded conflicting results regarding cancer incidence and causes of mortality in relation to control of growth hormone (gh) excess. |
2024-04-23 |
2024-04-26 |
Not clear |
| Anke Tönjes, Marleen Würfel, Marcus Quinkler, Ulrich J Knappe, Jürgen Honegger, Nina Krause-Joppig, Konrad Bacher, Timo Deutschbein, Sylvère Störmann, Jochen Schopohl, Sebastian M Meyhöfe. Pregnancy and acromegaly: clinical outcomes of retrospectively analysed data from the German acromegaly registry. Reproductive biology and endocrinology : RB&E. vol 22. issue 1. 2024-04-22. PMID:38650041. |
acromegaly is a rare disease caused by excessive growth hormone (gh) secretion, mostly induced by pituitary adenomas. |
2024-04-22 |
2024-04-26 |
Not clear |
| Daniel Cuevas-Ramos, Shlomo Melme. Acromegaly Type 1: A Representative Patient. JCEM case reports. vol 2. issue 4. 2024-04-18. PMID:38633358. |
biochemical evaluation, including insulin-like growth factor type 1 (igf-1) measurement and oral glucose loading with growth hormone (gh) measurement confirmed excess gh production and a diagnosis of acromegaly. |
2024-04-18 |
2024-04-20 |
Not clear |
| Busra Firlatan, Ugur Nadir Karakulak, Vedat Hekimsoy, Burcin Gonul Iremli, Incilay Lay, Deniz Yuce, Selcuk Dagdelen, Giray Kabakci, Tomris Erba. Evaluation of the relation between subclinical systolic dysfunction defined by four-dimensional speckle-tracking echocardiography and growth differentiation factor-15 levels in patients with acromegaly. Hormones (Athens, Greece). 2024-04-17. PMID:38632216. |
in patients with acromegaly, the long-term presence of elevated gh and igf-1 levels is associated with an unfavorable cardiovascular risk profile. |
2024-04-17 |
2024-04-20 |
Not clear |
| Federica Guaraldi, Francesca Ambrosi, Costantino Ricci, Luisa Di Sciascio, Sofia Asiol. Histopathology of growth hormone-secreting pituitary tumors: State of the art and new perspectives. Best practice & research. Clinical endocrinology & metabolism. 2024-04-13. PMID:38614953. |
somatotroph (gh) adenomas/pitnets typically arise from adenohypophysis and are biochemically active, leading to acromegaly and gigantism. |
2024-04-13 |
2024-04-16 |
Not clear |
| Kohei Oguni, Koichiro Yamamoto, Yasuhiro Nakano, Yoshiaki Soejima, Atsuhito Suyama, Ryosuke Takase, Miho Yasuda, Kou Hasegawa, Fumio Otsuk. Trends of correlations between serum levels of growth hormone and insulin-like growth factor-I in general practice. Frontiers in endocrinology. vol 15. 2024-04-10. PMID:38596224. |
of 642 patients, 33 patients were diagnosed with acromegaly, 21 were diagnosed with gh deficiency (ghd), and 588 were diagnosed with non-gh-related diseases (ngrd). |
2024-04-10 |
2024-04-12 |
Not clear |
| Kohei Oguni, Koichiro Yamamoto, Yasuhiro Nakano, Yoshiaki Soejima, Atsuhito Suyama, Ryosuke Takase, Miho Yasuda, Kou Hasegawa, Fumio Otsuk. Trends of correlations between serum levels of growth hormone and insulin-like growth factor-I in general practice. Frontiers in endocrinology. vol 15. 2024-04-10. PMID:38596224. |
in contrast to the positive correlations found between the levels of gh and igf-i in patients with acromegaly ( |
2024-04-10 |
2024-04-12 |
Not clear |
| Giuseppe Grande, Andrea Graziani, Luca DE Toni, Alberto Ferli. Proteomics for the identification of peripheral markers in pituitary disease. Minerva endocrinology. 2024-04-09. PMID:38591851. |
in this narrative mini-review, the role of proteomics is discussed with a particular focus on the few attempts of the application of proteomic platforms for the identification of new biomarkers in pituitary diseases, namely in acromegaly, gh deficiency and male secondary hypogonadism. |
2024-04-09 |
2024-04-11 |
Not clear |
| Maryam Thaer Saadi, Noor Ulhuda G Mohammed, Baydaa Ahmed Abed, Layla Othman Farhan, Isam Noori Salma. Validity of galactin-3 in acromegaly: comparison with traditional markers. Irish journal of medical science. 2024-03-23. PMID:38520613. |
acromegaly occurs due to overproduction of growth hormone (gh) and insulin-like growth factor-1 (igf-1). |
2024-03-23 |
2024-03-26 |
Not clear |
| Lucio Vilar, Luciana Ansaneli Naves, Manoel Ricardo Alves Martins, Antônio Ribeiro-Oliveir. "Micromegaly": Acromegaly with apparently normal GH, an entity on its own? Best practice & research. Clinical endocrinology & metabolism. 2024-03-22. PMID:38519400. |
"micromegaly": acromegaly with apparently normal gh, an entity on its own? |
2024-03-22 |
2024-03-25 |
Not clear |
| Lucio Vilar, Luciana Ansaneli Naves, Manoel Ricardo Alves Martins, Antônio Ribeiro-Oliveir. "Micromegaly": Acromegaly with apparently normal GH, an entity on its own? Best practice & research. Clinical endocrinology & metabolism. 2024-03-22. PMID:38519400. |
a small proportion of the patients with acromegaly present with apparently normal basal gh levels and suppressible gh levels despite increased igf-1 levels, a pattern called micromegaly by some authors. |
2024-03-22 |
2024-03-25 |
Not clear |
| Tomoyuki Hata, Yoshikatsu Uematsu, Ayumi Sugita, Hisashi Adachi, Sayaka Kato, Maki Hirate, Kei-Ichiro Ishikura, Ayaka Kaku, Hiroki Ohara, Naoki Kojima, Teisuke Takahashi, Tomofumi Kurokaw. A Potent Neutralizing Monoclonal Antibody to Human Growth Hormone Suppresses Insulin-Like Growth Factor-1 in female Rats. Endocrinology. 2024-03-19. PMID:38500360. |
acromegaly and gigantism are disorders caused by hypersecretion of growth hormone (gh), usually from pituitary adenomas. |
2024-03-19 |
2024-03-21 |
mouse |
| Ahmed Anass Guerboub, Jad Issouani, Kesly Jeny Joumas, Yassine Er Rahal. Acromegaly among a Moroccan population. The Pan African medical journal. vol 46. 2024-03-11. PMID:38465009. |
acromegaly is defined as an acquired dysmorphytic syndrome due to excessive secretion of growth hormone (gh) and consequently of insulin-like growth factor-1 (igf-1). |
2024-03-11 |
2024-03-14 |
Not clear |
| E O Mamedova, E G Przhiyalkovskaya, S A Buryakina, E V Bondarenko, A M Lapshina, M Yu Pikunov, Zh E Belaya, G A Melnichenk. [Ectopic acromegaly due to bronchial neuroendocrine tumors: the first description in Russia of three clinical cases]. Problemy endokrinologii. vol 70. issue 1. 2024-03-04. PMID:38433543. |
in the majority of cases the cause of acromegaly is a pituitary tumor producing gh. |
2024-03-04 |
2024-03-06 |
Not clear |